Literature DB >> 14766256

Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium.

Shuanfang Li1, Kelly Miner, Rick Fannin, J Carl Barrett, Barbara J Davis.   

Abstract

OBJECTIVES: Cyclooxygenase-1 and 2 (COX-1 and COX-2) play important roles in normal physiology and are often dysregulated in neoplastic tissues. The present study determines whether COX-1 and COX-2 are expressed in ovarian cancers and whether the pattern of expression of these enzymes reveals clues to their roles in this cancer.
METHODS: The expression of COX-1 and COX-2 proteins in 9 normal human ovaries, in 137 cases of ovarian cancers of epithelial origin (83 primary and 54 metastatic), and in 7 ovarian cancer cell lines was examined by immunohistochemistry and western analysis.
RESULTS: COX-1 protein was present in 95/137 (69.3%) of the total cancers studied, with 55/83 (66.3%) of the primary cancers and 40/54 (74.1%) of the metastatic cancers positive for protein. COX-2 was present in 97/137 (70.8%) of all cancers studied, with 53/83 (63.9%) of the primary cancers and 44/54 (81.5%) of the metastatic cancers positive for protein. Notably, the quickscores for COX-2-positive staining were significantly higher in metastatic cancers. Moreover, COX-2 immunostaining was frequently found at the advancing margin of tumor invasion or in new metastatic loci. COX-1 protein expression was observed in the ovarian surface epithelial cells, especially that of the inclusion cysts. COX-1 was also detected by western blot in seven of nine ovarian cancer cell lines. However, no COX-2 was detected in either normal epithelium or cancer cell lines.
CONCLUSION: COX-1 and COX-2 were expressed in every type of ovarian epithelial cancer, suggesting that each may contribute to the cancer development or progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766256     DOI: 10.1016/j.ygyno.2003.10.053

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.

Authors:  Takiko Daikoku; Dingzhi Wang; Susanne Tranguch; Jason D Morrow; Sandra Orsulic; Raymond N DuBois; Sudhansu K Dey
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

2.  Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.

Authors:  Lin Deng; Ding-Qing Feng; Bin Ling
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

3.  Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk.

Authors:  Galina Lurie; Kathryn L Terry; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Rachel T Palmieri; Daniel W Cramer; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2010-06-18       Impact factor: 2.506

4.  Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer.

Authors:  Paola Malerba; Brenda C Crews; Kebreab Ghebreselasie; Cristina K Daniel; Elma Jashim; Ansari M Aleem; Redoan A Salam; Lawrence J Marnett; Md Jashim Uddin
Journal:  ACS Med Chem Lett       Date:  2019-07-24       Impact factor: 4.345

5.  Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.

Authors:  Wei Li; Hong-Ru Jiang; Xiao-Li Xu; Jie Wang; Jun Zhang; Mei-Lin Liu; Ling-Yun Zhai
Journal:  Int J Mol Sci       Date:  2010-10-19       Impact factor: 5.923

6.  Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus).

Authors:  Dale Buchanan Hales; Yan Zhuge; Jo Ann Jaen Lagman; Kristine Ansenberger; Cassandra Mahon; Animesh Barua; Judith L Luborsky; Janice M Bahr
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

7.  Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.

Authors:  Wei Li; Hong-he Zhang; Ru-jun Xu; Guang-chao Zhuo; Ye-qing Hu; Juan Li
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

8.  Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.

Authors:  Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2009-04-02       Impact factor: 4.897

Review 9.  A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying Hen Gallus gallus.

Authors:  Purab Pal; Kara Nicole Starkweather; Karen Held Hales; Dale Buchanan Hales
Journal:  Comp Med       Date:  2021-07-29       Impact factor: 0.982

10.  Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.

Authors:  Naoko Sasamoto; Ana Babic; Allison F Vitonis; Linda Titus; Daniel W Cramer; Britton Trabert; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.